ONC201 for the Treatment of Newly Diagnosed H3 K27M-mutant Diffuse GliomaFollowing Completion of Radiotherapy: A Randomized, Double-Blind, Placebo Controlled, Multicenter Study (Brain Tumor)
Study of ONC201 After Radiation in Patients with Glioma
Sponsor: Chimerix
Enrolling: Male and Female Patients
IRB Number: AAAU7105
U.S. Govt. ID: NCT05580562
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to see if ONC201 is effective in treating participants with glioma when given following radiation therapy, how safe and tolerable ONC201 as compared to using placebo (a capsule that looks like ONC201 but does not contain any active drug), and to see how well ONC201 can improve quality of life and brain functioning in patients with glioma. ONC201 is a new drug that is being developed for treating people with glioma. ONC201 may help to remove tumor cells without affecting normal cells of the body. ONC201 is a first-in-class drug, which means it is a new drug having unique action, and it is not approved by the U.S. Food and Drug Administration (FDA) for treating glioma.
Aya Haggiagi, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Have you completed standard radiation therapy (radiotherapy)? Yes No
Are you pregnant, breastfeeding, or planning to become pregnant while participating in the study? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator